Epidemiology of Heterogenity in Type 2 Diabetes

2 型糖尿病异质性流行病学

基本信息

项目摘要

DESCRIPTION (provided by applicant): Several lines of evidence indicate that Type 2 (non-insulin-dependent) diabetes mellitus is a heterogeneous disease that results from a combination of abnormalities in both insulin secretion and insulin action. The causes of decreased insulin secretion in Type 2 diabetes are still not completely understood, but in a subgroup of Type 2 diabetic patients they may be related to an autoimmune destruction of the pancreatic beta-cells. We showed that in Type 2 diabetic patients the presence of GAD65 antibodies is strongly related to the use of insulin therapy. We now propose that GAD65 antibody-positive diabetes that we are observing is a unique subclass of Type 2 diabetes, which is associated with relatively severe insulin deficiency. It is important to note that these cases are all reasonably well documented as Type 2 diabetes rather than Type 1 and those they are older individuals and, clearly, are different than traditional Type 1 diabetes or young adults in regard to their clinical characteristics and needs for insulin. We hypothesize that this subset of older T2DM patients carrying GAD65 antibodies is unique in that is associated with severe insulin deficiency, with HLADQ susceptibility and with the development micro vascular disease. In contrast, diabetic patients who are not GAD65 antibody positive are probably primarily insulin resistant, have elevated blood insulin levels and are at primary risk for macro vascular disease. As a model for understanding the causes of insulin deficiency in GAD65 antibody positive older patients (>50 yr of age), we plan to evaluate the metabolic and genetic abnormalities in GAD65 autoantibody positive T2DM patients and compare these abnormalities with those of a subgroup of GAD65 antibody negative T2DM patients. The characterization of individuals at risk of developing this unique form of Type 2 diabetes is of public health interest because therapeutic strategies could potentially be instituted early enough to prevent the complications related with hyperglycemia and, possibly, the time of onset of insulin requirement. A more appropriate characterization of this subgroup of older Type 2 diabetic patients, presumably of autoimmune pathogenesis, will be of benefit to future research into the etiology, natural history as well as treatment of Type 2 diabetes mellitus.
描述(由申请人提供):一些证据表明2型(非胰岛素依赖型)糖尿病是一种异质性疾病,由胰岛素分泌和胰岛素作用异常共同引起。2型糖尿病患者胰岛素分泌减少的原因尚不完全清楚,但在2型糖尿病患者的一个亚组中,它们可能与胰腺β细胞的自身免疫破坏有关。我们发现,在2型糖尿病患者中,GAD65抗体的存在与胰岛素治疗的使用密切相关。我们现在提出,GAD65抗体阳性糖尿病是2型糖尿病的一个独特亚类,与相对严重的胰岛素缺乏有关。值得注意的是,这些病例都是2型糖尿病,而不是1型糖尿病,而且这些患者年龄较大,在临床特征和对胰岛素的需求方面,显然与传统的1型糖尿病或年轻人不同。我们假设携带GAD65抗体的老年T2DM患者的这个亚群是独特的,因为它与严重胰岛素缺乏、HLADQ易感性和微血管疾病的发展有关。相反,GAD65抗体不阳性的糖尿病患者可能主要是胰岛素抵抗,血液胰岛素水平升高,具有大血管疾病的主要风险。作为了解GAD65抗体阳性老年患者(50岁至50岁)胰岛素缺乏原因的模型,我们计划评估GAD65自身抗体阳性T2DM患者的代谢和遗传异常,并将这些异常与GAD65抗体阴性T2DM患者亚组的异常进行比较。具有发展这种独特形式的2型糖尿病风险的个体特征具有公共卫生利益,因为治疗策略有可能尽早制定,以预防与高血糖相关的并发症,并可能预防胰岛素需求开始的时间。对老年2型糖尿病患者的这一亚群进行更恰当的描述,可能是自身免疫发病机制,将有利于未来对2型糖尿病的病因、自然病史和治疗的研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MASSIMO T PIETROPAOLO其他文献

MASSIMO T PIETROPAOLO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MASSIMO T PIETROPAOLO', 18)}}的其他基金

A Novel Approach Applying CGM Metrics to Identify a Prediabetic State
一种应用 CGM 指标来识别糖尿病前期状态的新方法
  • 批准号:
    9012684
  • 财政年份:
    2013
  • 资助金额:
    $ 51.72万
  • 项目类别:
A Novel Approach Applying CGM Metrics to Identify a Prediabetic State
一种应用 CGM 指标来识别糖尿病前期状态的新方法
  • 批准号:
    8642867
  • 财政年份:
    2013
  • 资助金额:
    $ 51.72万
  • 项目类别:
Proteomics of Autoimmune Type 1 Diabetes
自身免疫 1 型糖尿病的蛋白质组学
  • 批准号:
    7276363
  • 财政年份:
    2005
  • 资助金额:
    $ 51.72万
  • 项目类别:
Proteomics of Autoimmune Type 1 Diabetes
自身免疫 1 型糖尿病的蛋白质组学
  • 批准号:
    7024667
  • 财政年份:
    2005
  • 资助金额:
    $ 51.72万
  • 项目类别:
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDM
NIDDM 胰岛细胞自身免疫的流行病学
  • 批准号:
    6517637
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:
Epidemiology of Heterogenity in Type 2 Diabetes
2 型糖尿病异质性流行病学
  • 批准号:
    6968683
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:
Epidemiology of Heterogenity in Type 2 Diabetes
2 型糖尿病异质性流行病学
  • 批准号:
    7119943
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDM
NIDDM 胰岛细胞自身免疫的流行病学
  • 批准号:
    6635180
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:
Epidemiology of Heterogenity in Type 2 Diabetes
2 型糖尿病异质性流行病学
  • 批准号:
    7485789
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:
EPIDEMIOLOGY OF ISLET CELL AUTOIMMUNITY IN NIDDM
NIDDM 胰岛细胞自身免疫的流行病学
  • 批准号:
    6285703
  • 财政年份:
    2001
  • 资助金额:
    $ 51.72万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 51.72万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 51.72万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了